Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

89Bio Inc (ETNB)

89Bio Inc (ETNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,554,730
  • Shares Outstanding, K 145,984
  • Annual Sales, $ 0 K
  • Annual Income, $ -367,080 K
  • EBIT $ -403 M
  • EBITDA $ -412 M
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.56

Options Overview Details

View History
  • Implied Volatility 90.38% ( +10.47%)
  • Historical Volatility 44.81%
  • IV Percentile 75%
  • IV Rank 35.68%
  • IV High 202.78% on 01/23/25
  • IV Low 28.02% on 08/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,592
  • Volume Avg (30-Day) 410
  • Put/Call OI Ratio 1.99
  • Today's Open Interest 27,388
  • Open Int (30-Day) 26,868

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.49
  • Number of Estimates 3
  • High Estimate -0.47
  • Low Estimate -0.51
  • Prior Year -0.48
  • Growth Rate Est. (year over year) -2.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.45 +11.01%
on 07/01/25
11.41 -8.06%
on 07/14/25
+0.49 (+4.90%)
since 06/18/25
3-Month
5.81 +80.62%
on 04/21/25
11.41 -8.06%
on 07/14/25
+4.43 (+73.10%)
since 04/17/25
52-Week
4.16 +152.16%
on 04/09/25
11.84 -11.40%
on 02/05/25
+2.16 (+25.93%)
since 07/18/24

Most Recent Stories

More News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 10.49 (-1.50%)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 10.49 (-1.50%)
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

ETNB : 10.49 (-1.50%)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 10.49 (-1.50%)
89bio to Participate in Upcoming Investor Conferences

ETNB : 10.49 (-1.50%)
89bio Reports First Quarter 2025 Financial Results and Corporate Updates

ETNB : 10.49 (-1.50%)
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips

Viking Therapeutics VKTX reported a first-quarter 2025 loss of 41 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents. The company had incurred a loss of 26 cents in the year-ago...

VKTX : 32.01 (-0.19%)
CTMX : 2.38 (unch)
ETNB : 10.49 (-1.50%)
ANIP : 66.30 (-2.56%)
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Shares of Valneva VALN rose 12% on Wednesday after the company announced that it has vaccinated the first participant in a phase II study evaluating its investigational Shigella vaccine, Shigella4V2 (S4V2).This...

CTMX : 2.38 (unch)
ETNB : 10.49 (-1.50%)
VALN : 6.55 (+0.77%)
ANIP : 66.30 (-2.56%)
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune...

ALLO : 1.2500 (+0.81%)
CTMX : 2.38 (unch)
ETNB : 10.49 (-1.50%)
ANIP : 66.30 (-2.56%)
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The...

CTMX : 2.38 (unch)
ETNB : 10.49 (-1.50%)
AKBA : 3.86 (-0.52%)
ANIP : 66.30 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis....

See More

Key Turning Points

3rd Resistance Point 11.17
2nd Resistance Point 10.99
1st Resistance Point 10.74
Last Price 10.49
1st Support Level 10.31
2nd Support Level 10.13
3rd Support Level 9.88

See More

52-Week High 11.84
Last Price 10.49
Fibonacci 61.8% 8.91
Fibonacci 50% 8.00
Fibonacci 38.2% 7.09
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar